Viking Therapeutics, Inc. (VKTX) Debt-to-equity % [USD] 2015 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Viking Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from 2015 to 2024.
  • Viking Therapeutics, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 4.06 %, a 66.2% decline year-over-year.
Debt-to-equity, Quarterly (% [USD])
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 4.06 -7.97 -66.2% Mar 31, 2024
Q4 2023 5.33 -5.17 -49.2% Dec 31, 2023
Q3 2023 6.68 -0.92 -12.1% Sep 30, 2023
Q2 2023 8.57 +2.12 +32.9% Jun 30, 2023
Q1 2023 12 +6.47 +116% Mar 31, 2023
Q4 2022 10.5 +5.27 +101% Dec 31, 2022
Q3 2022 7.59 +2.23 +41.6% Sep 30, 2022
Q2 2022 6.45 +1.47 +29.5% Jun 30, 2022
Q1 2022 5.57 +1.14 +25.7% Mar 31, 2022
Q4 2021 5.23 +1.34 +34.4% Dec 31, 2021
Q3 2021 5.36 +2.06 +62.4% Sep 30, 2021
Q2 2021 4.97 +2.06 +70.6% Jun 30, 2021
Q1 2021 4.43 +1.86 +72.3% Mar 31, 2021
Q4 2020 3.9 +1.67 +75.2% Dec 31, 2020
Q3 2020 3.3 +1.34 +68.3% Sep 30, 2020
Q2 2020 2.92 +1.15 +64.9% Jun 30, 2020
Q1 2020 2.57 +0.74 +40.5% Mar 31, 2020
Q4 2019 2.22 -0.21 -8.64% Dec 31, 2019
Q3 2019 1.96 -2.55 -56.5% Sep 30, 2019
Q2 2019 1.77 -10.8 -85.9% Jun 30, 2019
Q1 2019 1.83 -32.3 -94.6% Mar 31, 2019
Q4 2018 2.43 -110 -97.8% Dec 31, 2018
Q3 2018 4.51 -124 -96.5% Sep 30, 2018
Q2 2018 12.6 -73.7 -85.4% Jun 30, 2018
Q1 2018 34.1 -33.2 -49.3% Mar 31, 2018
Q4 2017 113 +43.9 +63.7% Dec 31, 2017
Q3 2017 129 +60.7 +89% Sep 30, 2017
Q2 2017 86.2 +24.1 +38.7% Jun 30, 2017
Q1 2017 67.3 +13.4 +24.9% Mar 31, 2017
Q4 2016 68.8 -346 -83.4% Dec 31, 2016
Q3 2016 68.2 +412 Sep 30, 2016
Q2 2016 62.2 Jun 30, 2016
Q1 2016 53.9 Mar 31, 2016
Q4 2015 415 Dec 31, 2015
Q3 2015 -344 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.